Francisco J Hernandez-Ilizaliturri

Summary

Affiliation: Roswell Park Cancer Institute
Country: USA

Publications

  1. doi request reprint Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype
    Francisco J Hernandez-Ilizaliturri
    Department of Medical Oncology and Immunology, Roswell Park Cancer Institute, Buffalo, New York, USA
    Cancer 117:5058-66. 2011
  2. ncbi request reprint CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymp
    Raymond I Cruz
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 48:2424-36. 2007
  3. ncbi request reprint MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical mod
    Juan J Gu
    Departments of aMedicine bImmunology cPathology dSurgical Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA
    Anticancer Drugs 24:1030-8. 2013
  4. ncbi request reprint Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20
    Sreeram Maddipatla
    School of Medicine, State University of New York at Buffalo, Buffalo, New York, USA
    Clin Cancer Res 13:4556-64. 2007
  5. ncbi request reprint Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo
    Nishitha Reddy
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Br J Haematol 140:36-45. 2008
  6. doi request reprint Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
    Myron S Czuczman
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Clin Cancer Res 14:1561-70. 2008
  7. pmc The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma
    Juan J Gu
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Br J Haematol 162:657-69. 2013
  8. pmc Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells
    Scott H Olejniczak
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    Blood 116:5605-14. 2010
  9. doi request reprint Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma
    Matthew J Barth
    Department of Pediatric Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Br J Haematol 156:490-8. 2012
  10. ncbi request reprint Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies
    Sapna Khubchandani
    Roswell Park Cancer Institute, Department of Medicine and Immunology, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Curr Opin Investig Drugs 10:579-87. 2009

Collaborators

Detail Information

Publications24

  1. doi request reprint Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype
    Francisco J Hernandez-Ilizaliturri
    Department of Medical Oncology and Immunology, Roswell Park Cancer Institute, Buffalo, New York, USA
    Cancer 117:5058-66. 2011
    ..Lenalidomide was previously shown to induce an overall response rate (ORR) of 28% in patients with relapsed/refractory DLBCL. It is currently unknown if response rates differ between patients with different DLBCL subtypes...
  2. ncbi request reprint CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymp
    Raymond I Cruz
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 48:2424-36. 2007
    ..Our current data provides a basis for further evaluation of alemtuzumab-based clinical trials for patients with rituximab-resistant NHL...
  3. ncbi request reprint MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical mod
    Juan J Gu
    Departments of aMedicine bImmunology cPathology dSurgical Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA
    Anticancer Drugs 24:1030-8. 2013
    ....
  4. ncbi request reprint Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20
    Sreeram Maddipatla
    School of Medicine, State University of New York at Buffalo, Buffalo, New York, USA
    Clin Cancer Res 13:4556-64. 2007
    ..Theoretically, synergistic antitumor activity should be observed by combining TRAIL-R mAbs with agents (e.g., rituximab) that activate the intrinsic apoptotic pathway...
  5. ncbi request reprint Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo
    Nishitha Reddy
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Br J Haematol 140:36-45. 2008
    ..Our positive preclinical data adds additional support for the evaluation of IMiDs plus rituximab in patients with relapsed/refractory B-cell lymphoma...
  6. doi request reprint Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
    Myron S Czuczman
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Clin Cancer Res 14:1561-70. 2008
    ..Future research is geared to identify drugs and/or biological agents that are effective against RRCL...
  7. pmc The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma
    Juan J Gu
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Br J Haematol 162:657-69. 2013
    ..Our pre-clinical data supports future clinical evaluation of CFZ in B-cell lymphoma. ..
  8. pmc Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells
    Scott H Olejniczak
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    Blood 116:5605-14. 2010
    ....
  9. doi request reprint Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma
    Matthew J Barth
    Department of Pediatric Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Br J Haematol 156:490-8. 2012
    ....
  10. ncbi request reprint Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies
    Sapna Khubchandani
    Roswell Park Cancer Institute, Department of Medicine and Immunology, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Curr Opin Investig Drugs 10:579-87. 2009
    ..In particular, patients with diffuse large B-cell lymphoma responded well to dacetuzumab; the drug is being pursued for this indication in phase II trials...
  11. ncbi request reprint Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches
    Francisco J Hernandez-Ilizaliturri
    Lymphoma Myeloma Service, Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
    Oncology (Williston Park) 23:546-53. 2009
    ..This two-part review summarizes treatment options for patients with relapsed/refractory DLBCL and stresses the emerging therapeutic challenges for patients who were previously exposed to rituximab...
  12. doi request reprint The use of galiximab in non-Hodgkin lymphoma
    Sanjay Vinjamaram
    Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14202, USA
    Clin Lymphoma Myeloma 8:277-82. 2008
    ..Ongoing and future studies are warranted to further evaluate the therapeutic role of galiximab in the treatment of patients with B-cell lymphomas in combination with rituximab or systemic chemotherapy...
  13. ncbi request reprint Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model
    Francisco J Hernandez-Ilizaliturri
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    Leuk Lymphoma 46:1775-84. 2005
    ..3%) compared to rituximab alone (13.3%) or in combination with peg-GM-CSF (26.7%). Increasing neutrophil counts via cytokine stimulation may play an important role in augmenting rituximab-associated antitumor activity...
  14. ncbi request reprint Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma
    Francisco J Hernandez-Ilizaliturri
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Adv Hematol Oncol 2:606-18. 2004
    ..In this report we provide an overview of recent developments in target-specific therapies and review past, ongoing, and future research tiling this diverse group of exciting novel agents...
  15. doi request reprint Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression
    Scott H Olejniczak
    Departments of Immunology and Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Clin Cancer Res 14:1550-60. 2008
    ..In an attempt to define strategies to overcome rituximab resistance, we sought to determine the chemotherapy sensitivity of our rituximab-resistant cell lines (RRCL)...
  16. pmc A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients
    Taimur Sher
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Br J Haematol 154:104-10. 2011
    ..We concluded that VDT is a tolerable and an effective regimen capable of inducing high response rates and can be employed in patients considered to be poor candidates for steroid-based treatment regimens...
  17. doi request reprint Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms
    Wasif Riaz
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Immunol Res 46:192-205. 2010
    ..In this review article, we will provide an overview of various rituximab-associated cytotoxic mechanisms and novel strategies to improve mAb activity against B-cell lymphoma...
  18. pmc Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas
    Elizabeth A Brem
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Br J Haematol 153:599-611. 2011
    ..Defining the molecular events triggered by obatoclax is necessary to further its clinical development and identify potential biomarkers that are predictive of response...
  19. pmc Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma
    Ping Chiao Tsai
    Department of Immunology and Medical Oncology, Roswell Park Cancer Institute, Buffalo, New York, NY 14263, USA
    Clin Cancer Res 18:1039-50. 2012
    ..The aim of this research was to further investigate the contribution of CD20 antigen expression to rituximab activity and define the mechanisms responsible for CD20 downregulation in rituximab-resistant cell lines (RRCL)...
  20. doi request reprint Novel therapeutic strategies for cutaneous T-cell lymphoma in advanced stages
    Lillian Kun
    Department of Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY
    Semin Hematol 51:35-41. 2014
    ....
  21. ncbi request reprint Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies
    Francisco J Hernandez-Ilizaliturri
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Oncology (Williston Park) 23:610-5. 2009
    ....
  22. doi request reprint Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis
    Andrew M Evens
    Andrew M Evens, Tufts University School of Medicine, Boston Aimee Kroll Desrosiers, University of Massachusetts Medical School, Worcester, MA Ranjana Advani and Stavroula Otis, Stanford University Medical Center, Stanford, CA Oliver W Press and Linda M Parker, Fred Hutchinson Cancer Research Center, Seattle, WA Izidore S Lossos, Liat Nadav Dagan, and Jose Sandoval, University of Miami School of Medicine, Miami, FL Julie M Vose, University of Nebraska Medical Center, Omaha, NE Francisco J Hernandez Ilizaliturri, Roswell Park Cancer Institute, Buffalo Ramsey Abdallah and John P Leonard, Weill Cornell Medical College, New York, NY Barrett K Robinson, Indiana University School of Medicine, Indianapolis, IN Jessica L Yarber and Leo I Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL Kristie A Blum, The Ohio State University, Columbus, OH Christopher R Flowers, Emory University, Atlanta, GA Thomas M Habermann, Mayo Clinic, Rochester, MN and Nancy L Bartlett, Washington University School of Medicine, St Louis, MO
    J Clin Oncol 31:4132-9. 2013
    ..Lymphoma is the fourth most frequent cancer in pregnancy; however, current clinical practice is based largely on small series and case reports...
  23. doi request reprint Clinical spectrum and prognosis of follicular lymphoma with blastoid transformation: case series and a review of the literature
    Gayatri Vaidyanathan
    Department of Internal Medicine, State University of New York at Buffalo, Elm and Carlton Streets, Buffalo, NY, 14263, USA
    Ann Hematol 90:955-62. 2011
    ..C-MYC rearrangements are common in FL-BT and may play a role in the progression from FL to FL-BT or the poor clinical outcomes observed. Periodic updates from academic institutions treating FL-BT may improve patient care...
  24. ncbi request reprint Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab
    Jeyanthi Ramanarayanan
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Br J Haematol 127:519-30. 2004
    ..Our findings suggest that Bcl-2 downregulation by G3139, followed by the administration of rituximab is an efficient anti-tumour strategy associated with improved survival in lymphoma-bearing SCID mice...